OncRef

Clinical Trial: NCT03634241

Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:M.D. Anderson Cancer Center
Information Provided By:M.D. Anderson Cancer Center
Last Update Posted:2026-04-16

Study Overview

Brief Summary

This phase II trial studies how well pembrolizumab works in preventing lung cancer patients with stage I-II non-small cell lung cancer or high-risk pulmonary nodules. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Official Title

Single-Arm, Phase II of Immunotherapy With Pembrolizumab for the Prevention of Lung Cancer (IMPRINT-Lung)

Conditions

Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8

Intervention / Treatment

  • Biological: Pembrolizumab
  • Other: Quality-of-Life Assessment
  • Procedure: Computed Tomography
  • Procedure: Biospecimen Collection

Other Study ID Numbers

  • 2018-0366
  • NCI-2018-01588
  • 2018-0366

Start Date (Actual)

2018-11-13

Primary Completion Date (Actual)

2026-01-27

Study Completion Date (Actual)

2026-03-11

Enrollment (Actual)

45

Study Type

Interventional

Phase

Phase 2